What does this research mean for the field?

The entry of biosimilars for anticancer biologics is associated with lower average sales prices, reduced market share for reference products, and decreased financial burden for both payers and patients. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess market dynamics and evaluate the financial implications for payers and patients following biosimilar entry for bevacizumab, rituximab, and trastuzumab.

August 29, 2026JAMA Oncology

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients

View Full Paper

Ask AI

Bookmark

Authors

XLXiaoyu LiuUniversity of California, Los Angeles XXXiaoyi Xu ZLZ John LuUniversity of California, Los Angeles

Discussion

Member takes

Implication

Retrospective cohort study demonstrates decreased drug costs and reference market share in cancer patients after biosimilar entry, indicating substantial payer and patient savings.

Key Points

To assess market dynamics and evaluate the financial implications for payers and patients following biosimilar entry for bevacizumab, rituximab, and trastuzumab.
Conducted a retrospective cohort study analyzing commercial (Merative MarketScan) and Medicare databases from July 2019 to December 2024 among N=14,655 cancer patients receiving bevacizumab, rituximab, or trastuzumab.
Categorized patients by their 12-month postinitiation utilization pattern into exclusive biosimilar use, exclusive reference product use, reference-to-biosimilar switching, and biosimilar-to-reference switching.
Exclusive biosimilar use occurred in 59.4% of patients (n=8,710), exclusive reference product use in 32.5% (n=4,760), reference-to-biosimilar switching in 6.9% (n=1,015), and biosimilar-to-reference switching in 1.2% (n=170).
Average sales price for reference biologics fell by an average of 3.8% annually, while reference product market share decreased by 30.0% annually in commercial plans and 31.5% in Medicare Part B.
Patients using only biosimilars experienced a $3,820 lower mean monthly payer cost and a $39.50 lower mean monthly out-of-pocket cost compared with those using only reference products.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6a9299ac8e5d7d1fc0c11cb0 https://doi.org/10.1001/jamaoncol.2026.3128

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study demonstrates decreased drug costs and reference market share in cancer patients after biosimilar entry, indicating substantial payer and patient savings.

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider